The estimated Net Worth of Fund, L.P.10 X Capital Mana... is at least $15.2 million dollars as of 14 June 2018. Fund Mana owns over 151,860 units of Galectin Therapeutics Inc stock worth over $7,260,414 and over the last 14 years Fund sold GALT stock worth over $7,989,211.
Fund has made over 12 trades of the Galectin Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Fund sold 151,860 units of GALT stock worth $1,307,515 on 14 June 2018.
The largest trade Fund's ever made was exercising 500,000 units of Galectin Therapeutics Inc stock on 27 January 2014 worth over $1,500,000. On average, Fund trades about 108,688 units every 90 days since 2011. As of 14 June 2018 Fund still owns at least 2,649,786 units of Galectin Therapeutics Inc stock.
You can see the complete history of Fund Mana stock trades at the bottom of the page.
Fund's mailing address filed with the SEC is 1099 FOREST LAKE TERRACE1099 FOREST LAKE TERRACE, , NICEVILLENICEVILLE, FLFL, 3257832578.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr et Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: